Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study - Concepedia

Concepedia

Publication | Closed Access

Erenumab in the prevention of high‐frequency episodic and chronic migraine: Erenumab in Real Life in Italy (EARLY), the first Italian multicenter, prospective real‐life study

122

Citations

19

References

2020

Year

Piero Barbanti, Cinzia Aurilia, Gabriella Egeo, Luisa Fofi, Sabina Cevoli, Bruno Colombo, Massimo Filippi, Fabio Frediani, Francesco Bono, Licia Grazzi,

Headache The Journal of Head and Face Pain

Abstract

Erenumab 70 mg is effective, safe, and well tolerated in real life. Easily obtainable clinical features might be of help in predicting patient's responsiveness.

References

	Year	Citations

Page 1